19:42 : BioMimetic Therapeutics (BMTI) tanks in the post-trading session after ... -
BioMimetic Therapeutics (BMTI) tanks in the post-trading session after the FDA says its proposed bone-graft device, Augment, wouldn't be approved without more information from previous studies. The company says it plans ...